Forte Biosciences, Inc. (FBRX) Stock

Forte Biosciences, Inc. (FBRX) is a Healthcare stock trading at $17.85 (as of 2026-06-18), with a market capitalization of $268.06M and a trailing P/E of -3.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing the FB-102 program for autoimmune diseases, including vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Valuation — source: SEC EDGAR (first-party)
Price$17.85
Market Cap$268.06M
P/E Ratio-3.9
EV / EBITDA-2.5
Price / Book5.90
DCF Value (model)$-56.98
DCF Upside vs Price-419.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$36000.00
Net Margin-176433.3%
Return on Equity-180.2%
Current Ratio2.75
Valuation vs Sector & Industry
Stock P/E-3.9
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-118.7%
vs Industry-122.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFEDERATED HERMES, INC. ($45.73M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPaul A. Wagner
Employees14
CountryUS
IPO Date2017-04-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Rocket Pharmaceuticals, Inc. (RCKT)
  • Nature's Sunshine Products, Inc. (NATR)
  • Palisade Bio, Inc. (PALI)
  • enGene Holdings Inc. (ENGN)
  • Aclaris Therapeutics, Inc. (ACRS)
  • Relmada Therapeutics, Inc. (RLMD)
  • Aura Biosciences, Inc. (AURA)
  • Avalo Therapeutics, Inc. (AVTX)
FBRX earnings history · FBRX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.